TOL 3021
Alternative Names: BHT-3021; DNA plasmid vaccine for type 1 diabetes - Bayhill Therapeutics; RG 7426Latest Information Update: 13 Sep 2024
At a glance
- Originator Stanford University
- Developer Tolerion
- Class Antihyperglycaemics; Diabetes mellitus vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Gene transference; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Type 1 diabetes mellitus
Most Recent Events
- 27 Apr 2022 TOL 3021 is still in phase II clinical trials in Type 1 diabetes mellitus in USA (IM) (NCT03895437)
- 08 Dec 2020 Tolerion withdraws the phase IIb DAWN trial for Type 1 diabetes mellitus (In children, In adolescents, In adults) prior to enrolment, due to modification in the clinical development plan (IM) (NCT03794960)
- 08 Dec 2020 Tolerion withdraws the phase IIb DAY trial for Type 1 diabetes mellitus (In children, In adolescents, In adults) prior to enrolment, due to modification in the clinical development plan (IM) (NCT03794960)